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Circulating endothelial progenitor cells (EPCs) play a role in the regeneration of damaged brain tissue. 
However, the relationship between circulating EPC levels and functional recovery in intracerebral 
hemorrhage (ICH) has not yet been tested. Therefore, our aim was to study the influence of circulating 
EPCs on the outcome of ICH. Forty-six patients with primary ICH (males, 71.7%; age, 72.7 ± 10.8 years) 
were prospectively included in the study within 12 hours of symptom onset. The main outcome variable 
was good functional outcome at 12 months (modified Rankin scale ≤2), considering residual volume 
at 6 months as a secondary variable. Circulating EPC (CD34+/CD133+/KDR+) levels were measured by 
flow cytometry from blood samples obtained at admission, 72 hours and day 7. Our results indicate 
that patients with good outcome show higher EPC numbers at 72 hours and day 7 (all p < 0.001). 
However, only EPC levels at day 7 were independently associated with good functional outcome at 12 
months (OR, 1.15; CI95%, 1.01–1.35) after adjustment by age, baseline stroke severity and ICH volume. 
Moreover, EPC levels at day 7 were negatively correlated to residual volume (r = −0.525; p = 0.005). In 
conclusion, these findings suggest that EPCs may play a role in the functional recovery of ICH patients.
Intracerebral hemorrhage (ICH) represents 10–15% of all strokes1. Early mortality ranges between 32% and 52% 
within the first 30 days, only 10% of patients will live independently after 1 month, and only one in five patients 
will be autonomous at 6 months2. Despite being the most severe cerebral vascular disorder, there is no specific 
pharmacological treatment. Early surgery, even if does not increase the disability or death rate at 6 months, might 
have only a small clinically relevant survival advantage for patients with spontaneous superficial ICH without 
intraventricular hemorrhage3. Therefore, it is imperative to search for new therapeutic options. In this regard, the 
beneficial effects of bone marrow-derived progenitor cells (BMPCs) have been demonstrated in animal models 
of ICH, as evidenced by reduced tissue loss, immature neuron formation, synaptogenesis, neuronal migration, 
and neurological improvement4–7. In clinical studies regarding patients after acute ischemic stroke, the increase of 
circulating endothelial progenitor cells (EPCs), a subtype of BMPCs, has been associated with good neurological 
and functional outcome, reduced infarct growth and neurological improvement8–13. Likewise, high blood levels 
of circulating CD34+ progenitor cells have been associated with improved functional outcome at three months 
and reduced brain injury in patients with primary ICH14. Furtheremore, a recent study involving 16 patients with 
ICH has shown increased levels of circulating EPCs15. However, the role of circulating EPCs in the recovery of 
ICH patients is largely unknown. Our aim was therefore to study the influence of circulating EPCs in the outcome 
of ICH.
Results
We prospectively studied 46 patients with primary ICH (71.7% male, mean age 72.7 ± 10.8 years). Median [quar-
tiles] NIHSS score at admission was 11 [5,16], and mean time from stroke onset was 4.7 ± 4.6 hours.
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Primary Outcome. Table 1 shows the main characteristics of patients classified by outcome groups. Nineteen 
(41.3%) patients showed good functional outcome at 12 months. Patients with good functional outcome were 
younger and showed milder stroke severity, lower rate of ventricular extension and leukoaraiosis, and smaller 
ICH and edema volumes at admission. Likewise, patients with good outcome (n = 19) showed higher EPC num-
bers at 72 hours (18.2 ± 5.5 vs. 11.2 ± 7.3; p = 0.003) and at day 7 (22.7 ± 5.3 vs. 13.5 ± 9.1; p = 0.001), but not at 
admission (14.2 ± 5.1 vs. 10.9 ± 6.1; p = 0.108) (Fig. 1). However, only EPC levels at day 7 were independently 
associated with good functional outcome at 12 months (OR, 1.15; CI95%, 1.01 to 1.35, p = 0.039) after adjustment 
by age, baseline stroke severity, and ICH volume (Table 2).
Secondary Outcomes. Figure 2 shows the correlation of circulating EPCs at admission, 72 hours and day 
7 with ICH residual volume at 6 months. No correlation was found between circulating EPC levels at admission 
and residual ICH volume at 6 months (Pearson correlation coefficient, r = − 0.158; p = 0.412). However, an expo-
nential negative correlation was found between residual ICH volume and EPC levels at 72 hours (r = − 0.421; 
p = 0.032), and at day 7 (r = − 0.525; p = 0.005). In the multivariate analysis, both circulating levels of EPCs at 




n = 27 p
Age (years) 67.7 ± 10.7 76.1 ± 9.8 0.010
Male, (%) 73.7 70.4 0.806
Time from stroke onset, h 5.1 ± 4.5 4.4 ± 4.8 0.562
Vascular risk factors
 History of hypertension, (%) 63.2 63.0 0.989
 History of diabetes, (%) 10.5 11.1 0.950
 History of atrial fibrillation, (%) 10.5 25.9 0.195
 History of hyperlipidemia, (%) 36.8 28.5 0.363
 Smoking habit, (%) 10.5 3.7 0.356
 Alcohol consumption, (%) 21.1 14.8 0.583
Biochemistry and vital signs at admission
 Body temperature (°C) 36.4 ± 0.8 36.1 ± 0.5 0.110
 Systolic blood pressure (mm Hg) 165.9 ± 29.6 162.2 ± 27.9 0.665
 Diastolic blood pressure (mm Hg) 88.2 ± 21.0 86.4 ± 21.2 0.781
 Glucose levels (mg/dL) 123.0 ± 34.2 140.2 ± 37.8 0.121
 Fibrinogen (mg/dL) 407.7 ± 98.4 451.5 ± 108.0 0.174
 Leucocytes (×103/mL) 9.3 ± 2.2 10.2 ± 3.7 0.344
 Platelets (×103/mL) 232.9 ± 44.1 232.1 ± 68.1 0.965
 INR 1.2 ± 0.5 1.6 ± 1.2 0.077
Neuroimaging findings
 ICH volume at admission (cc) 15.4 ± 12.6 42.3 ± 36.6 < 0.0001
 Edema volume at admission (cc) 24.7 ± 14.3 51.4 ± 40.5 0.007
 Ventricular extension, (%) 15.8 55.6 < 0.0001
 Leukoaraiosis, (%) 5.3 51.9 < 0.0001
Clinical characteristics
 NIHSS at admission 7 [5, 10] 13 [9, 16] < 0.0001
Diagnosis
 Topographic: 0.847
  – Deep, (%) 63.2 66.7
  – Lobar, (%) 36.8 33.3
 Etiologic: 0.271
  – Hypertensive, (%) 63.1 44.0
  – Amyloid, (%) 31.6 32.0
  – Anticoagulants, (%) 0 16.0
  – Undetermined, (%) 5.3 8.0
Number of EPCs (CD34+/CD133+/KDR+)
 EPCs at admission 14.2 ± 5.1 10.9 ± 6.1 0.108
 EPCs at 72 hours 18.2 ± 5.5 11.2 ± 7.3 0.003
 EPCs at day 7 22.7 ± 5.3 13.5 ± 9.1 < 0.0001
Table 1.  Baseline clinical characteristics, vascular risk factors, stroke subtype, biochemical parameters and 
neuroimaging findings in patients with good or poor outcome at 12 months. INR: International Normalized 
Ratio; ICH: Intracerebral hemorrhage; NIHSS: National Institute of Health Stroke Scale.
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−0.28; p = 0.005) were independently associated with residual ICH volume at 6 months. However, only circulat-
ing EPC levels at day 7 (B, − 0.54; CI95%, − 0.93 to − 0.15; p = 0.009) were independenly associated with resid-
ual ICH volume at 6 months after adjusting by baseline stroke severity, as well as ICH and edema volumes at 
admission.
On the other hand, no correlation was found between circulating EPC levels at day 7 and NIHSS at admission 
(r = − 0.237; p = 0.178). However, a significant negative correlation was observed between circulating EPC levels 
at day 7 and NIHSS at discharge (r = − 0.607; p < 0.0001), at 3 months (r = − 0.570; p < 0.0001) and at 12 months 
(r = − 0.591; p < 0.0001).
Discussion
Main results and clinical relevance. To the best of our knowledge, this study is the first prospective analysis 
that evaluates the relationship between circulating levels of EPCs (defined as CD34+/CD133+/KDR+ cells) and 
brain injury in patients with ICH. Remarkably, circulating EPC levels at day 7 were independently associated with 
good functional outcome at 12 months. This favourable effect on the primary endpoint was supported by resid-
ual ICH volume reduction at 6 months and milder neurological deficits. Overall, these findings support cellular 
therapy with EPCs as a new therapeutic approach for patients with ICH, a severe vascular disorder with currently 
no specific pharmacological treatment.
Possible mechanisms underlying EPC effects on recovery and ICH residual volume. We have 
demonstrated that circulating EPCS increase at day 7 in response to ICH, and that the greater the magnitude of 
this increases the better the clinical outcome at 12 months. These findings are in line with experimental stud-
ies demonstrating the beneficial effects of BMPCs in animal ICH models as evidenced by reduced tissue loss, 
immature neuron formation, synaptogenesis, neuronal migration and neurological improvement4–7. The fact that 
patients with good outcome showed higher EPC levels at day 7, but not at admission, supports the hypothesis that 
EPCs can mediate processes of chronic vessel repair and neurorepair. Furthermore, supporting this hypothesis, 
we found a negative correlation between increased levels of EPCs and smaller ICH residual volume at 6 months 
as well as milder neurological deficits. However, the mechanisms by which EPCs are associated with better func-
tional outcome and with smaller residual ICH volume need further investigation. We hypothesize that this may 
occur through a triple mechanism: (a) the repairing of the damaged vessels through re-endotelization as previ-
ously shown in ventricular assist devices in humans16,17 (b) the developing of new vessels through neovasculari-
zation18–20 and (c) the paracrine action of EPCs promoting angiogenesis21–24. A possible fourth mechanism may 
add up in the acute phase of ICH, where EPCs may play an early role in protecting the blood-brain barrier (BBB), 
as some studies have indeed suggested in ischemic stroke25. This is consistent with other data from this study 
Figure 1. Temporal profile of mean circulating EPC numbers in ICH patients with good or poor outcome 
at 12 months. 
OR (CI95%), p OR (CI95%), adjusted p
EPCs at 72 hours 1.18 (1.04 to 1.34), p = 0.009 1.10 (0.95 to 1.29), p = 0.189
EPCs at day 7 1.31 (1.09 to 1.58), p = 0.002 1.15 (1.01 to 1.35), p = 0.039
NIHSS at admission 0.94 (0.81 to 1.09), p = 0.405
ICH volume at admission 0.98 ( 0.93 to 1.03), p = 0.383
Age 0.95 (0.86 to 1.04), p = 0.295
Table 2.  Crude and adjusted OR of good outcome at 12 months for EPCs numbers at 72 hours and day 7. 
NIHSS: National Institute of Health Stroke Scale; ICH: Intracerebral hemorrhage.
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showing that reduced flow mediated dilation (which is positively correlated with EPCs; r = 0.602; p < 0.0001) 
holds a negative association with ICH and edema growth at 48–72 hours (data not shown).
On the other hand, previous studies by our group have observed that higher levels of growth factors at 72 hours 
after ICH are independently associated with a good functional outcome at 3 months, lesion volume reduction and 
relative neurological improvement ≥ 50% at day 9026. Likewise, we have previously demonstrated that higher lev-
els of growth factors are associated with higher levels of circulating EPCs in human ischemic stroke27. Therefore, 
it is tempting to postulate that the beneficial effects of growth factors in ICH may be mediated by EPCs.
Figure 2. Scatterplot showing the correlation of circulating EPCs at admission, 72 hours and day 7 with 
ICH residual volume at 6 months. No correlation was found between circulating EPC levels at admission 
and ICH residual volume at 6 months (Pearson correlation coefficient, r = − 0.158; p = 0.412). However, 
an exponential relation was found between ICH residual volume and EPC levels at 72 hours (r = − 0.421; 
p = 0.032), and at day 7 (r = − 0.525; p = 0.005).
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Study limitations. This study has some limitations. First, we did not include a control group. Nevertheless, 
a previous study had already shown increased levels of circulating EPCs in ICH patients compared with a control 
group15. Another limitation is that we did not determine EPC levels at longer intervals after the acute phase of 
ICH, so we cannot conclude if good recovery was associated with an acute and transient increase in EPC levels or 
if it was the result of a sustained increase of these progenitor cells during the follow-up. However, the favourable 
effect of the EPC level increase at day 7 was independent of other important prognostic variables at baseline. Lack 
of consensus over optimal definition for EPCs and the best measurement method may justify many contradictory 
results concerning EPCs up to date. We have used CD34, CD133 and KDR markers, as well as flow cytometry 
analysis because both techniques are amply used and recommended for EPC characterization and counting28. We 
have not directly measured functionality of EPCs. Nevertheless, the most accepted method for EPC characteri-
zation is flow cytometry, and several studies in ischemic stroke patients have virtually come to the same results 
using this technique and cell culture for CFU-EC counts (which best expresses functionality of EPCs) suggesting 
a parallelism relationship between EPC numbers and functionality8,10,11.
Conclusions. In conclusion, a higher increase in circulating EPC levels at day 7 is associated with a better 
outcome and reduced ICH residual volume in ICH patients. However, whether if EPCs are able to incorporate 
into brain hemorrhagic areas and promote neurorepair in humans remains to be clarified. Finally, the role of 
EPCs as a therapeutic tool able to promote chronic neurorepair of brain tissue damaged by an ICH needs to be 
further explored.
Methods
Study population and patient characteristics. Between October 2012 and February 2014, 59 consecu-
tive patients with a first-ever primary non-traumatic ICH of less than 12 hours from clinical onset and previously 
independent for their daily living activities were prospectively included in the study. Patients with previously 
altered functional capacity (modified Rankin Scale (mRS ) ≥ 1)29 (n = 3), chronic inflammatory diseases (n = 2), 
severe hepatic (n = 1) or renal (n = 1) diseases, cancer (n = 2) or infectious disease in the 15 days prior to inclu-
sion (n = 1) were excluded. Furthermore, 2 patients did not accept their participation in the study, so a total of 46 
patients were finally included.
This research was carried out in accordance with the Declaration of Helsinki of the World Medical Association 
(2008) and approved by the Ethics Committee of the Servizo Galego de Saúde. Informed consent was obtained 
from each patient or their relatives after full explanation of the procedures.
Clinical variables. All patients were admitted to an acute stroke unit and treated according to the guidelines 
of the Cerebrovascular Diseases Study Group of the Spanish Society of Neurology30. Etiological diagnosis was 
made according the Guidelines for the management of spontaneous intracerebral hemorrhage in adults from 
the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research 
Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group31. Medical history 
recording potential vascular risk factors, blood and coagulation tests, 12-lead ECG, and chest radiography was 
obtained at admission.
To evaluate neurologic deficit, the National Institute of Health Stroke Scale (NIHSS)32 was performed at 
admission, 24 and 72 hours, at discharge, and at 3 and 12 months. Functional outcome was evaluated at discharge 
and at 3 and 12 months by using the mRS29. Both NIHSS and mRS were evaluated by internationally certified 
neurologists.
Antihypertensive treatment with intravenous labetalol or urapidil was administered in case of systolic blood 
pressure > 185 mmHg or diastolic blood pressure > 105 mmHg. Low-dose subcutaneous heparin was used for the 
prevention of deep vein thrombosis and pulmonary thromboembolism.
Neuroimaging studies. A CT study was performed at admission, at 72 hours, between days 4th–7th, and at 
6 months. ICH and perihematomal edema volumes were calculated by a standard planimetric method using a 
semiautomated process. The perimeter of appropriate high and low-attenuation zones was traced, calculating 
lesion areas for each slice which were multiplied by slice thickness to yield lesion volumes. The residual cavity vol-
ume of ICH at 6 months was determined using the same volumetric method described; each volume calculation 
was done three times, the mean value being taken as definitive.
ICH topography was classified as lobar when it predominantly affected the cortical or subcortical white matter 
of the cerebral lobes, or as deep when it was limited to the internal capsule, the basal ganglia or the thalamus. The 
presence of intraventricular extension of the hematoma was also recorded.
All neuroimaging evaluations were made by the same neuroradiologist, who had no knowledge of the patients’ 
clinical or laboratory results.
EPC quantification in peripheral blood by Flow Cytometry. Circulating EPC leves were measured by flow cytom-
etry according to methods described elsewhere33 in blood samples obtained at admission, 72 hours and at day 7. 
Blood samples were processed within 1–2 hours after collection by a single researcher who had no knowledge 
of the patients’ clinical or radiological results. In brief, circulating EPCs were analyzed for the expression of 
specific surface antigens using direct flow cytometry (BD FACSAria IIu, BD, Franklin Lakes, NJ, USA). Cells 
were labelled with FITC-conjugated anti-CD34 (BD, Franklin Lakes, NJ, USA), PE-conjugated anti-KDR (R&D 
Systems, Minneapolis, MN, USA) and APC-conjugated anti-CD133 (clone AC133 from Miltenyi Biotec, Bergisch 
Gladbach, Germany) monoclonal antibodies. We considered EPCs as triple CD133+ /CD34+ /KDR+ staining 
cells in the mononuclear cell fraction. In all analyses, 5 × 105 events were acquired, scored using a FACSAria IIu 
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analyzer (BD, Franklin Lakes, NJ, USA), and processed using the PC FACSDiva software program (BD, Franklin 
Lakes, NJ, USA). Cell count was always expressed per 106 events.
Outcome Variables. The primary endpoint was good functional outcome (mRS ≤ 2) at 12 months. ICH Residual 
volume at 6 months and the evolution of NIHSS score during the first 12 months were evaluated as secondary 
outcome variables.
Statistical Analysis. The statistical analysis was conducted in SPSS 18.0 (SPSS, Chicago, IL, USA) for Mac.
Sample size calculation. Sample size was calculated using the statistical EPIDAT software (http://www.
sergas.es/MostrarContidos_N3_T01.aspx?IdPaxina= 62714), based on an EPC levels increase > 200% in patients 
with acute ischemic stroke who showed good functional outcome according to previous studies8. The minimum 
sample size calculated to detect this effect was made accepting an alpha level of 5% and an 80% power.
Statistical tests for univariate analysis. Results were expressed as percentages for categorical variables 
and as mean (SD) or median and range (25th and 75th percentiles) for continuous variables depending on whether 
their distribution was normal or not. The Kolmogorov-Smirnov test was used to assess normality. Proportions 
were compared using the chi-square or Fisher test, while the continuous variables between groups were compared 
with the Student’s t or the Mann-Whitney tests depending on whether their distribution was normal or not. 
Bivariate correlations were performed using Pearson’s coefficient (normally distributed variables) or Spearman 
coefficient (variables without normal distribution).
Statistical tests for multivariate analysis. The association of EPCs and good functional outcome 
(mRS ≤ 2 at 12 months) was assessed using logistic regression analysis; the influence on residual ICH volume was 
assessed by multiple linear regression models. Both logistic regression analysis and multivariable linear regression 
models were adjusted for those variables with a proven biological relevance for each endpoint in order to avoid 
spurious associations. Residual plots were examined to detect potential non-linear relationships between the 
outcome variable and continuous independent variables. Results were expressed as adjusted odds ratios (ORs) or 
Beta estimate with the corresponding 95% confidence intervals (95% CI).
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